Abecma denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for abecma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Apply Quantity Limits to Abecma

Abecma (idecabtagene vicleucel) is a single-infusion CAR-T cell therapy — by its nature, it is a one-time treatment manufactured from the individual patient's own cells. A quantity-limit denial in this context typically does not mean the insurer is limiting repeat doses in the conventional sense. Instead, it usually arises from one of these scenarios: (1) the claim was submitted in a way that triggered an automated quantity-limit edit because the billing units exceeded what the policy's coding logic expects for a single administration; (2) the policy restricts coverage to a single lifetime course and a prior authorization or claim for the same therapy already exists in the patient's record; or (3) the authorization was approved for a different quantity than what was billed.

## Your Right to Appeal

Quantity-limit denials are appealable under the same federal frameworks as all coverage denials. ACA §2719 provides access to independent external review after internal appeals are exhausted; ERISA §503 governs employer-sponsored plans. External review must generally be requested within four months of the final internal denial. Expedited review is available when standard timelines would seriously jeopardize health.

## Building Your Appeal

1. Identify the specific quantity-limit basis — request the denial reason in detail. Ask Humana to identify the specific quantity edit or policy provision triggered, and obtain the written policy language. 2. Billing audit — work with the treatment center's billing team to confirm the units, revenue codes, and HCPCS codes submitted match Abecma's standard billing conventions for a single CAR-T infusion. A coding correction alone may resolve the denial without a formal appeal. 3. Confirm no duplicate authorization — verify with Humana and the treating center that no prior authorization or claim for the same service exists in the patient's record that could be creating a conflict. 4. Clinical letter if lifetime-limit is at issue — if Humana's policy limits Abecma to one lifetime course and the issue is a second course, the treating oncologist should write a letter documenting the clinical rationale, the patient's current disease status, the time elapsed since the prior course, and the applicable NCCN guideline recommendation, without asserting any specific numeric threshold as if it were universal.

## Criteria-Mapping Structure

Obtain the exact quantity-limit language from Humana's published policy and from the denial letter. Create a two-column table matching each policy requirement to the corresponding billing record, authorization document, or clinical chart note. If the denial is a billing artifact, include the corrected claim as an exhibit.